![Medicen Paris Region devient partenaire de l’initiative européenne EIT Health](https://ala.associates/wp-content/uploads/2017/03/Medicen-EIT-Health-1.png)
![Medicen Paris Region devient partenaire de l’initiative européenne EIT Health](https://ala.associates/wp-content/uploads/2017/03/Medicen-EIT-Health-1.png)
![NovAliX signs insourcing agreement with UCB Biopharma](https://ala.associates/wp-content/uploads/2017/03/IMG_7502-1080x675.jpg)
NovAliX signs insourcing agreement with UCB Biopharma
![Medicen Paris Region strengthens ties with Medteq cluster and Greater Montreal ecosystem](https://ala.associates/wp-content/uploads/2017/02/Lajoux-Christian-RE.legouhy05-e1486379409454-1080x675.jpg)
Medicen Paris Region strengthens ties with Medteq cluster and Greater Montreal ecosystem
![Sebia signs agreement with Janssen Biotech to develop a multiple myeloma IVD test](https://ala.associates/wp-content/uploads/2017/01/Benoit-Adelus-e1485785546925.jpg)
Sebia signs agreement with Janssen Biotech to develop a multiple myeloma IVD test
![Domain Therapeutics and Merck enter into a license and collaboration agreement](https://ala.associates/wp-content/uploads/2017/01/20081027-Domain_Therapeutics-08.jpg)
Domain Therapeutics and Merck enter into a license and collaboration agreement
![GPCR: Domain Therapeutics grants Alkermes a non-exclusive license for its BioSens-All™ technology](https://ala.associates/wp-content/uploads/2016/11/Pascal-Neuville-2016-e1478702603628-992x675.jpg)
GPCR: Domain Therapeutics grants Alkermes a non-exclusive license for its BioSens-All™ technology
![French technology clusters Route des Lasers and Elopsys merge to become ALPHA-RLH](https://ala.associates/wp-content/uploads/2016/12/Fusion-ALPHA-RLH-1080x675.png)
French technology clusters Route des Lasers and Elopsys merge to become ALPHA-RLH
![Novasep and Japanese agent AR Brown extend partnership](https://ala.associates/wp-content/uploads/2016/11/Alain-Lamproye_008-1080x675.jpg)